A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...
In men with localized, intermediate-risk prostate cancer, stereotactic body radiation therapy (SBRT) was associated with less toxicity at 2 years but a higher rate of biochemical failure at 3 years ...
What is stereotactic radiation therapy for prostate cancer? How does it compare to other treatments?
Prostate cancer is Australia's most commonly diagnosed cancer. One in six men will be diagnosed by the time they turn 85. Cancers are abnormal groups of cells that grow uncontrollably and start ...
After a comprehensive two-year follow-up, researchers found that MRI-guided stereotactic body radiotherapy (SBRT) for prostate cancer significantly reduced long-term side effects and improved quality ...
SAN DIEGO — With just five fractions of stereotactic body radiation therapy (SBRT), men with low- or intermediate-risk prostate cancer can have 5-year disease control as good as that provided by ...
Researchers found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, is as safe as conventional treatment, with similar side effects and a ...
The primary end points were FISST and local control (LC) rates of lesions that received SBRT. The secondary end point was overall survival (OS) after SBRT. To calculate FISST, event was defined as the ...
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing ...
As part of the “Speaking Out” series, a radiation oncologist discusses the benefits of MRI-guided stereotactic body radiation therapy. Dr. Matthew Solhjem, a radiation oncologist with Providence ...
Stereotactic body radiotherapy and hormone treatment resulted in 40.1% 12-month progression-free survival in a recent study. Administration of radiotherapy in conjunction with hormone treatment has ...
The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...
People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results